<DOC>
	<DOCNO>NCT00741819</DOCNO>
	<brief_summary>This 24-month , multi-center , prospective , open-label , safety evaluation PAH subject follow transition stable dose inhale iloprost ( Ventavis ) . Subjects evaluate safety throughout course study secondary assessment conduct Baseline , Week 6 , Week 12 , Months 6 , 12 , 18 24 follow initiation treprostinil sodium .</brief_summary>
	<brief_title>Safety Evaluation Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis Pulmonary Arterial Hypertension ( PAH ) Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>Between 18 75 year age PAH diagnosis define follow WHO Group I category : idiopathic/familial , associate unrepaired repair congenital systemictopulmonary shunt ( repair &gt; /= 5 year ) , associate collagen vascular disease , associate HIV , associate appetite suppressant/toxin use Baseline sixminute walk distance ( 6MWD ) &gt; /= 250 meter Currently receive Ventavis stable current dose 30 day prior Baseline If currently receive approve background therapy ( i.e . endothelin receptor antagonist phosphodiesterase5inhibitor ) must stable dose 30 day prior Baseline Previous test ( e.g . right heart catheterization , echocardiography ) consistent diagnosis PAH Nursing pregnant Has acute concomitant disease ( e.g . portal hypertension , chronic thromboembolic disease , pulmonary venoocclusive disease , etc ) accept part inclusion criterion atrial septostomy History uncontrolled sleep apnea , leftsided heart disease , parenchymal lung disease Use investigational drug within 30 day Baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>pulmonary arterial hypertension</keyword>
	<keyword>PAH</keyword>
	<keyword>treprostinil sodium</keyword>
	<keyword>inhalation</keyword>
	<keyword>ventavis</keyword>
	<keyword>iloprost</keyword>
</DOC>